1. Intoduction {#sec1-medicina-55-00047}
==============

Stroke is a set of devastating and debilitating diseases that are the result of blockage to blood vessels in the brain. Stroke is the third debilitating and second deadliest disease in the world, and is responsible for about 10% of all deaths. Five and a half million people die annually from ischemic stroke (IS), and the resulting disability-adjusted life years (DALYs) loss was equivalent to US \$44 million in 2011 \[[@B1-medicina-55-00047],[@B2-medicina-55-00047]\]. Released statistics show that low- and middle-income countries account for 70% of strokes and 87% of stroke-related deaths---and its incidence rate has doubled in these countries over the past four decades \[[@B3-medicina-55-00047]\]. Commonly, the mean age of stroke patients is 15 years younger and the mortality rate of stroke patients is higher in countries with low and middle income compared to countries with high income \[[@B4-medicina-55-00047]\]. The World Health Organization (WHO) indicated stroke as the second greatest cause of mortality in Iran, killing 41,600 people in 2012, equivalent to 10.5% of all deaths \[[@B5-medicina-55-00047]\]. Stroke mostly occurs at peak productive age. Despite its massive impact on the socio-economic development of countries, this growing crisis has received very slight attention so far. Stroke is largely preventable and treatable, and is an avoidable tragedy for patients, families, and societies. Stroke can be divided into two major types: brain ischemia (due to thrombosis, embolism, systemic hypo-perfusion or blood disorders) and brain hemorrhage \[[@B6-medicina-55-00047]\]

IS represents approximately 10% of all cerebrovascular diseases. The exact etiology of IS is complicated; it has numerous risk factors such as diabetes mellitus, hypertension, and age. Also, the complexity of genetic and environmental factors could be involved \[[@B7-medicina-55-00047]\]. It is believed that, similar to other vascular complications, genetic variants play a key role in IS susceptibility \[[@B8-medicina-55-00047],[@B9-medicina-55-00047],[@B10-medicina-55-00047]\].

Thrombophilia is a widespread range of changes that promote conditions for vascular thrombosis due to hematological changes that induce blood hypercoagulability; these can be inherited or acquired \[[@B11-medicina-55-00047],[@B12-medicina-55-00047]\]. Among the inherited factors of thrombophilia, the four most common genetic markers are Factor V Leiden (*FVL*, G1691A), methylenetetrahydrofolate reductase polymorphisms (*MTHFR C677T* and *A1298C)*, prothrombin gene (*FII*, *G20210A*), and plasminogen activator inhibitor-1 (*PAI-1*) variants---and their relation to various vascular diseases is known \[[@B13-medicina-55-00047]\].

Previous studies reported an association between elevated levels of homocysteine---which is an endothelial toxin---and the risk of vascular events, including IS \[[@B14-medicina-55-00047]\]. Evidence showed that the 677TT and 1298CC genotypes (mutant homozygous) of the *MTHFR* gene are associated with hyperhomocysteinemia (HHcy) and have a critical role in modulating plasma homocysteine concentrations---which predispose the carrier to thrombosis and IS \[[@B15-medicina-55-00047],[@B16-medicina-55-00047]\]. The effects of the *MTHFR* C677T polymorphism were highest in the regions where the diet has a low folate content \[[@B17-medicina-55-00047]\]. Regarding *FVL*, the substitution of arginine by glutamine at 506 amino acid residue increases its resistance to degradation by activated protein C and accentuates the venous thromboembolism risk. At position 20210 of the 3′-UTR region of the Factor II gene, a G to A transition has been associated with higher levels of prothrombin and more risk for venous thrombosis \[[@B16-medicina-55-00047]\]. Recently, the association between several polymorphisms in the 3′-UTR region of the *MTHFR* gene ([Figure 1](#medicina-55-00047-f001){ref-type="fig"}) and susceptibility to various diseases has been reported \[[@B16-medicina-55-00047],[@B18-medicina-55-00047]\].

Although the exact mechanisms that lead to IS in young adults are not well understood, controversial studies in recent years showed evidence on the causality of IS in patients with methylenetetrahydrofolate reductase, prothrombin, and *FVL* gene polymorphisms. Therefore, in this study the possible effects of common *MTHFR C677T*, *A1298C*, *C2572A*, and *C4869G*, as well as *FVL* and prothrombin *G20210A* polymorphisms on IS in young patients were evaluated in a southeastern Iranian population.

2. Materials and Methods {#sec2-medicina-55-00047}
========================

2.1. Participants {#sec2dot1-medicina-55-00047}
-----------------

This case-control study was carried out from May 2016 to September 2017 on 106 cases with IS and 157 control subjects who were matched to the IS patients for age and sex. All patients and controls were younger than 50 years in age. Informed consent was obtained from all participants, and the study was approved by the ethics committee of the Zahedan university of medical sciences (code 7185). The inclusion criteria for IS patients was the existence of IS at the present hospital admission, which the computerized tomography (CT) or magnetic resonance imaging (MRI) scan and clinical symptoms confirmed. The exclusion criteria were patients who had experienced an acute hemorrhagic stroke or other neurological diseases, a known malignancy, renal and liver disease, hematologic disorders, and hypothyroidism. Cases with IS of a cardioembolic origin (e.g., with atrial fibrillation) in both groups were also excluded.

The questionnaire was completed by skilled nurses to collect data on demographic, clinical, and lifestyle characteristics of patients and controls.

Blood pressure was measured for all subjects in the seated position with the back supported and legs uncrossed. Participants rested for at least 5 min before the assay. Blood pressure was measured using a routine mercury sphygmomanometer device (Omron HEM-711 IntelliSense, Tokyo, Japan). We repeated all assays twice and the average values were considered.

Smokers were known as those who smoked tobacco regularly up to six months prior with constant or intermittent usage (at least one cigarette per week).

2.2. Genomic DNA Extraction and Genotyping {#sec2dot2-medicina-55-00047}
------------------------------------------

Blood samples taken from the study subjects were drained into tubes containing Ethylenediaminetetraacetic acid (EDTA) and kept in a −20 °C freezer. To extract genomic DNA, the salting out method was performed on peripheral blood leukocytes. To analyze *MTHFR*, *FVL*, and prothrombin polymorphisms, the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was performed as previously described \[[@B19-medicina-55-00047],[@B20-medicina-55-00047]\].

2.3. Statistical Analysis {#sec2dot3-medicina-55-00047}
-------------------------

SPSS version 20 (SPSS Inc., Chicago, IL, USA) was employed to analyze the data. The Kolmogorov--Smirnov test was used to evaluate the normality of quantitative variables. The clinical data and demographic characteristics of the study groups were compared by the Fisher exact and student *t* tests. Logistic regression analyses, adjusted for age and gender, were employed to calculate the associations between genotypes and disease based on Odds Ratio (OR) and 95% Confidence Interval (CI). HaploView software was used to analyze the frequency and Linkage Disequilibrium (LD) of haplotypes. *p* \< 0.05 was considered the level of significance.

3. Results {#sec3-medicina-55-00047}
==========

3.1. Demographic Characteristics {#sec3dot1-medicina-55-00047}
--------------------------------

[Table 1](#medicina-55-00047-t001){ref-type="table"} presents the clinical and demographic characteristics of 106 patients with IS (\<50 years), and 157 sex- and age-matched controls. There was no statistically significant difference in the systolic and diastolic blood pressures between the two groups. TG, total cholesterol, and LDL cholesterol levels were higher in the IS group, but the differences were not statistically significant.

3.2. MTHFR Polymorphisms and Ischemic Stroke Risk {#sec3dot2-medicina-55-00047}
-------------------------------------------------

The alleles and genotypes' frequency of *MTHFR* polymorphisms in IS patients and the control group are shown in [Table 2](#medicina-55-00047-t002){ref-type="table"}.

3.3. MTHFR C677T Polymorphism {#sec3dot3-medicina-55-00047}
-----------------------------

The frequency of individuals carrying the *MTHFR 677 CT* genotype was statistically higher in the IS group, and this genotype was associated with a 1.9-fold greater risk of IS (OR 1.9 (95% CI 1.1--3.4); *p* = 0.028). The 677TT genotype was more frequent in IS patients, but not statistically different (OR 1.8 (95% CI 0.7--5); *p* = 0.26). Moreover, the *MTHFR C677T* polymorphism was associated with a higher risk of IS in dominant (OR 1.9 (95% CI 1.1--3.3); *p* = 0.019) but not recessive models (OR 1.5 (95% CI 0.6--4.2); *p* = 0.4).

3.4. MTHFR A1298C Polymorphism {#sec3dot4-medicina-55-00047}
------------------------------

The frequency of individuals carrying the *MTHFR* 1298AC and CC genotypes did not differ between the two groups, therefore this polymorphism was not associated with IS risk.

3.5. MTHFR C2572A Polymorphism {#sec3dot5-medicina-55-00047}
------------------------------

The frequencies of the *MTHFR* 2572AC and CC genotypes were not statistically different between patients and controls (*p* = 0.12 and *p* = 0.23 respectively), and this variant was not associated with IS in dominant and recessive models.

3.6. MTHFR C4869G Polymorphism {#sec3dot6-medicina-55-00047}
------------------------------

The frequency of the *MTHFR 4869CG* genotype was significantly reduced in the IS group, and this genotype was associated with decreased IS risk (OR 0.4 (95% CI 0.2--0.9); *p* = 0.016). In addition, *MTHFR C4869G* polymorphism was associated with lower risk of IS in the dominant (OR 0.4 (95% CI 0.2--0.8); *p* = 0.01) model.

3.7. Haplotype Analysis of MTHFR Polymorphisms {#sec3dot7-medicina-55-00047}
----------------------------------------------

[Table 3](#medicina-55-00047-t003){ref-type="table"} shows the results from the haplotype analysis of *MTHFR C4869G*, *C2572A*, *A1298C*, and *C677T* polymorphisms in IS and control groups. The CCAC haplotype was the most frequent haplotype in IS and control groups. The frequency of individuals carrying the CAAT haplotype was statistically higher in IS patients than controls (8.5 vs. 3.2%) compared to other haplotypes, and this haplotype was associated with a 2.8-fold higher risk of IS (OR 2.8 (95% CI 1.3--6.2); *p* = 0.01). However, the frequency of the GAAC haplotype was significantly lower in IS patients than controls (3.8 vs. 9.2%) compared to other haplotypes, and this haplotype could be a protective genetic factor against IS (OR 0.4 (95% CI 0.2--0.9); *p* = 0.02). [Figure 2](#medicina-55-00047-f002){ref-type="fig"} shows the linkage disequilibrium between *MTHFR* polymorphisms in the total studied population.

3.8. FVL G1691A and Prothrombin G20210A Polymorphisms and Ischemic Stroke Risk {#sec3dot8-medicina-55-00047}
------------------------------------------------------------------------------

The frequency of the *FVL* 1691GA genotype was higher in IS patients; however, the difference was not significant (OR 2 (95% CI 0.9--4.3); *p* = 0.09). We did not observe the *FVL* 1691AA genotype in IS and control groups. Moreover, we did not find the prothrombin 20210A allele in our study population.

4. Discussion {#sec4-medicina-55-00047}
=============

Hyperhomocysteinemia (HHcy) is a pathological complication described by an increase in the plasma level of total homocysteine \[[@B21-medicina-55-00047]\]. Numerous epidemiological investigations have shown the role of HHcy in premature atherosclerosis and thrombotic disease susceptibility. Evidence has revealed that HHcy leads to endothelial dysfunction and causes apoptotic cell death in various cells---including endothelial ones \[[@B22-medicina-55-00047],[@B23-medicina-55-00047]\]. HHcy is also known to be associated with improved thrombotic disorders and has been considered a risk factor for atherosclerosis and thrombosis---therefore, the elevated levels of plasma homocysteine have been related with susceptibility to IS, coronary artery disease (CAD), and pregnancy hypertension \[[@B24-medicina-55-00047],[@B25-medicina-55-00047],[@B26-medicina-55-00047]\].

Evidence has shown that elevated homocysteine levels could be due to genetic defects in enzymes involved in its metabolism, or environmental factors such as vitamin B12 or folic acid deficiency \[[@B27-medicina-55-00047]\]. *MTHFR* plays an important role in the metabolism of homocysteine. *MTHFR* reduces the 5,10-methylene tetrahydrofolate to 5-methyltetrahydrofolate and plays the methyl donor role in methionine production from homocysteine \[[@B28-medicina-55-00047]\].

Genome-wide association studies (GWAS) on plasma homocysteine level have reported on the association between the *MTHFR* variant (C667T, rs1801133) and elevated homocysteine levels---therefore the *MTHFR*-encoding gene has been introduced as a genetic determinant of HHcy \[[@B29-medicina-55-00047]\].

Several polymorphisms in the *MTHFR* gene have been found to be associated with various diseases. The *C667T* polymorphism in the *MTHFR* gene (alanine to valine substitution in exon 4), is the most consistently associated with total homocysteine (tHcy), resulting in decreased enzyme activity and elevated homocysteine levels. The *MTHFR A1298C* polymorphism (glutamate to alanine substitution in exon 7) results in a thermos-labile form of enzyme, which may play a role in the regulation of the plasma homocysteine level \[[@B30-medicina-55-00047]\].

Moreover, several polymorphisms have been identified in the 3′-UTR region of the *MTHFR* gene, and are potentially located in the microRNAs (miRNAs) binding sites. The *MTHFR* 2572C \> A and 4869C \> G variants are located in the 3′-UTR region, and bioinformatics analysis showed that these substitutions create binding sites for several miRNAs, leading to suppression of the translation stage and thus regulating its expression \[[@B19-medicina-55-00047]\].

Factor V is an important protein in the blood coagulation cascade, and its deficiency plays a role in bleeding disorders. *Factor V Leiden* (*G1691A*, rs6025) is a modified form of Factor V leading to activated protein C resistance (APCR) and increased blood clotting. It is introduced as one of the essential genetic risk factors for inherited thrombophilia \[[@B31-medicina-55-00047]\].

In the present study, the frequency of the *MTHFR 677CT* genotype was higher in IS patients than in controls. In addition, the *MTHFR C677T* polymorphism was associated with increased risk of IS in the dominant model. There was no association between the *MTHFR A1298C* and *C2572A* variants and IS. The *MTHFR 4869CG* genotype was associated with lower IS risk, and this polymorphism could be a protective factor in the dominant model. The CCAC haplotype was the most frequent haplotype in both the IS and control groups. Haplotype analysis revealed that the CAAT haplotype of the *MTHFR C4869G*, *C2572A*, *A1298C*, and *C677T* polymorphisms was higher, while the GAAC haplotype was significantly lower in IS patients compared to other haplotypes---and these haplotypes could be considered as risk and protective factors, respectively. There are numerous studies on the relationship between the *MTHFR C677T* and A1298C variants and IS in various ages---and several meta-analyses were performed to assess them. In the meta-analysis performed by Song et al. on 22 case-control studies from January 2000 to October 2014, the *C677T* polymorphism was introduced as a risk factor for IS in dominant, recessive, and allelic models \[[@B15-medicina-55-00047]\]. In another meta-analysis on 40 case-control studies, Chen et al. reported the relation between the *C677T* variant and IS risk in young and middle-aged Asian males \[[@B32-medicina-55-00047]\]. Kumar et al. presented the effect of the *C677T* variant on IS risk in Asians in dominant and recessive models, as well as in Caucasians in recessive but not dominant models \[[@B33-medicina-55-00047]\]. However, Cui showed the association between this polymorphism and adult IS in Asians and Caucasians, but not in Africans \[[@B34-medicina-55-00047]\]. Abhinand et al. analyzed 72 studies and found that this polymorphism may lead to a 1.3-fold increased risk of IS \[[@B35-medicina-55-00047]\].

A meta-analysis by Zhang et al. included 15 studies showing the effect of *A1298C* polymorphism on adult IS, mainly in Asian populations \[[@B36-medicina-55-00047]\]. Sarecka-Hujar et al. performed a meta-analysis to evaluate the relationship between this variant and IS in pediatric patients in eight case-control studies, and found no association between this polymorphism and IS in children---for neither the recessive nor the additive models nor the allelic models \[[@B37-medicina-55-00047]\]. Wei et al. (490 case-control studies) reported the association between *MTHFR A1298C* and *C677T* polymorphisms and IS \[[@B38-medicina-55-00047]\].

Despite the numerous studies and meta-analyses performed on the association between these common polymorphisms and IS, the published reports on the possible effects of variants in the 3′-UTR region of the *MTHFR* gene are few. Recently, Kim et al. analyzed four polymorphisms in the 3′-UTR region of the *MTHFR* gene and IS. Despite the current study results, they found an association between *2572CC* and *6685TT* genotypes and IS in the cardioembolism subgroup. In spite of our findings, they showed no association between *MTHFR* 4869C \> G polymorphism and IS \[[@B39-medicina-55-00047]\]. There was an association between *MTHFR* rs142884651 polymorphism in the 3′-UTR region and decreased risk of IS found in a study conducted by Shi et al. They showed that the *MTHFR* 4869C \> G variant was associated with increased risk of IS (TC and CC vs. TT), with a poor short-term IS outcome. Indeed, they found elevated serum tHcy levels in *MTHFR* rs868014TC or CC genotypes \[[@B40-medicina-55-00047]\].

In addition, we observed a higher frequency of the *FVL 1691GA* genotype in IS patients, but the difference was not significant. We did not find the prothrombin *20210A* allele in our study population.

Similar to other thrombophilia-related genes, several studies assessed the relationship between *FVL G1691A* and prothrombin *G20210A* polymorphisms and IS in various ethnic groups---and meta-analyses were performed to evaluate the possible effects of these variants on IS susceptibility. In the two separate meta-analyses performed by Hamiz et al. and Bentley et al., prothrombin *G20210A*, *FVL G1691A*, and *MTHFR C677T* polymorphisms were considered as risk factors for IS \[[@B41-medicina-55-00047],[@B42-medicina-55-00047]\]. However, Peck et al. showed a significant protective role of the Factor V Leiden mutation against hemorrhagic stroke \[[@B43-medicina-55-00047]\]. Although Alhazzani et al. reported a significant relationship between Factor V G1691A polymorphism and susceptibility to IS in a dominant model, when they classified the patients in groups according to age, they showed a significant relation between Factor V G1691A polymorphism and IS risk in patients onset at a young age but not at an old age (\>40 years) \[[@B44-medicina-55-00047]\].

Some limitations were in the current study that may affect our findings, particularly the relatively low sample size because of the small population in the southeast of Iran. In addition, the different ethnic groups in southeastern Iran and environmental factors could be consider as the other limitations of this investigation. Indeed, if the homocysteine levels in IS patients and controls had been assayed, the findings would have become more appreciated---mainly regarding the possible effects of *MTHFR* polymorphisms on homocysteine levels.

5. Conclusions {#sec5-medicina-55-00047}
==============

*MTHFR* C677T polymorphism was associated with increased risk of IS in the dominant model. However, there was no relation between *A1298C* and *C2572A* polymorphisms and IS risk. The *MTHFR* C4869G polymorphism was associated with lower risk of IS in the dominant model. Moreover, for the first time we found that the *CAAT* and *GAAC* haplotypes of *MTHFR* C4869G, *C2572A*, *A1298C*, and *C677T* polymorphisms were associated with higher and lower risk of IS, respectively.
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medicina-55-00047-t001_Table 1

###### 

Demographic characteristics of ischemic stroke (IS) patients and control group.

  -----------------------------------------------------------------
  Variable                   Controls\    IS\           *p*-Value
                             n = 157      n = 106       
  -------------------------- ------------ ------------- -----------
  Age (years)                37.2 ±10.8   36.9 ± 10.3   0.8 ^a^

  Sex (male/female)          69/88        42/64         0.5 ^b^

  Smoking (n, %)             28 (17.8)    29 (27.4)     0.07 ^b^

  SBP (mmHg)                 117 ± 18     118 ± 24      0.7 ^a^

  DBP (mmHg)                 75 ± 8.4     77 ± 17       0.3 ^a^

  Triglycerides (mg/dL)      100 ± 64     109 ± 79      0.3 ^a^

  Total Cholesterol(mg/dL)   148 ± 35     160 ± 39      0.08 ^a^

  LDL Cholesterol (mg/dL)    87± 22       92 ± 25       0.1 ^a^

  HDL Cholesterol (mg/dL)    39 ± 10      39 ± 11       0.9 ^a^
  -----------------------------------------------------------------

^a^ Independent *t*-test, the data represent mean ± standard deviation (SD), ^b^ Fisher exact test. SPB: systolic blood pressure, DBP: diastolic blood pressure, LDL: low density lipoprotein, HDL: high density lipoprotein

medicina-55-00047-t002_Table 2

###### 

Allelic and genotypic frequency of *MTHFR* and *FV* polymorphisms in ischemic stroke patients and the control group.

  --------------------------------------------------------------------------------------------------------------
  Polymorphism                                       IS\          Control\     *p*-Value   Odds Ratio (95% CI)
                                                     (n = 106)    (n = 157)                
  --------------------- ---------------------------- ------------ ------------ ----------- ---------------------
  ***MTHFRC677T***\     ***genotype***                                                     
  ***rs1801133***                                                                          

                        CC, n (%)                    66 (62.3)    119 (75.8)               1

                        CT, n (%)                    32 (30.2)    30 (19.1)    0.028       1.9 (1.1--3.4)

                        TT, n (%)                    8 (7.5)      8 (5.1)      0.26        1.8 (0.7--5)

                        Dominant (CT + TT vs. CC)                              0.019       1.9 (1.1--3.3)

                        Recessive (TT vs. CT + CC)                             0.4         1.5 (0.6--4.2)

                        *Allele*                                                           

                        C, n (%)                     164 (77.4)   268 (85)                 1

                        T, n (%)                     48 (22.6)    46 (15)      0.02        1.7 (1.1--2.7)

  ***MTHFRA1298C***     ***genotype***                                                     

  ***rs1801131***       AA, n (%)                    72 (67.9)    120 (76.4)               1

                        AC, n (%)                    31 (29.3)    32 (20.4)    0.1         1.6 (0.9--2.9)

                        CC, n (%)                    3 (2.8)      5 (3.2)      1           1 (0.2--4.3)

                        Dominant (AC + CC vs. AA)                              0.13        1.5 (0.9--2.7)

                        Recessive (CC vs. AC + AA)                             0.9         0.9 (0.2--3.8)

                        *Allele*                                                           

                        A, n (%)                     175 (83)     272 (87)                 1

                        C, n (%)                     37 (17)      42 (13)      0.2         1.4 (0.9--2.2)

  ***MTHFR C2572A***\   ***genotype***                                                     
  ***rs4846049***                                                                          

                        AA, n (%)                    25 (23.6)    25 (15.9)                1

                        AC, n (%)                    50 (47.2)    84 (53.5)    0.12        0.6 (0.3--1.2)

                        CC, n (%)                    31 (29.2)    48 (30.6)    0.23        0.7 (0.3--1.3)

                        Dominant (AC + CC vs. AA)                              0.12        0.6 (0.3--1.1)

                        Recessive (CC vs. AC + AA)                             0.8         0.9 (0.6--1.6)

                        *Allele*                                                           

                        A, n (%)                     100 (47)     134 (43)                 

                        C, n (%)                     112 (53)     180 (57)     0.3         0.8 (0.6--1.2)

  ***MTHFR C4869G***\   ***genotype***                                                     
  ***rs1537514***                                                                          

                        CC, n (%)                    93 (87.7)    117 (74.5)               1

                        CG, n (%)                    13 (12.3)    38 (24.2)    0.016       0.4 (0.2--0.9)

                        GG, n (%)                    0            2 (1.3)      1           \-

                        Dominant (CG + GG vs. CC)                              0.01        0.4 (0.2--0.8)

                        Recessive (GG vs. CG + CC)                             \-          \-

                        *Allele*                                                           

                        C, n (%)                     199 (94)     272 (87)                 

                        G, n (%)                     13 (6)       42 (13)      0.009       0.4 (0.2-0.8)

  ***FVL G1691A***\     ***genotype***                                                     
  ***rs6025***                                                                             

                        GG, n (%)                    90 (84.9)    144 (91.7)               

                        GA, n (%)                    16 (15.1)    13 (8.3)     0.09        2 (0.9--4.3)

                        AA, n (%)                    0 (0)        0 (0)        \-          \-

                        *Allele*                                                           

                        G, n (%)                     196 (92.5)   301 (96)                 

                        A, n (%)                     16 (7.5)     13 (4)       0.12        1.9 (0.9--4)
  --------------------------------------------------------------------------------------------------------------
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###### 

Haplotype analysis of *MTHFR C4869G*, *C2572A*, *A1298C*, and *C677T* polymorphisms in ischemic stroke patients and the control group.

  Haplotypes   IS            Control       *p*-Value   OR (95% CI)
  ------------ ------------- ------------- ----------- ----------------
  CCAC         73 (0.344)    127 (0.404)   0.17        0.8 (0.5--1.1)
  CAAC         60 (0.283)    84 (0.268)    0.76        1.1 (0.7--1.6)
  GAAC         8 (0.0377)    29 (0.092)    0.02        0.4 (0.2--0.9)
  CCCC         16 (0.0750)   16 (0.051)    0.28        1.5 (0.7--3.1)
  CAAT         18 (0.0849)   10 (0.032)    0.01        2.8 (1.3--6.2)
  CCAT         11 (0.052)    14 (0.045)    0.83        1.2 (0.5--2.6)
  CCCT         8 (0.038)     13 (0.041)    0.96        0.9 (0.4--2.2)
  CACT         8 (0.0380)    5 (0.016)     0.15        2.4 (0.8--7.5)
  GCAC         3 (0.014)     9 (0.029)     0.38        0.5 (0.1--1.8)
  CACC         4 (0.019)     3 (0.010)     0.43        2 (0.4--9)
